Skip to content

APIMEDS PHARMACEUTICALS US, INC.: 10-Q filed 2025-08-19

What APIMEDS PHARMACEUTICALS US, INC. reported in its quarterly report filed 2025-08-19 (fiscal Q2 2025): 30 published measures, 82 facts as tagged in accession 0001213900-25-078507.

This filing

Form
10-Q (quarterly report)
Filed
2025-08-19
Fiscal period
fiscal Q2 2025
Accession
0001213900-25-078507 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All APIMEDS PHARMACEUTICALS US, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2025-06-3010,546,681USD
At 2024-12-3113,057USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2025-06-30809,002USD
At 2024-12-311,371,178USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2025-06-309,737,679USD
At 2025-03-31-1,760,518USD
At 2024-12-31-1,358,121USD
At 2024-06-30-713,967USD
At 2024-03-31-264,604USD
At 2023-12-3131,869USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2025-06-308,735,323USD
At 2024-12-313,455USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-2,662,193USD91
2025-01-01 to 2025-06-30-3,064,590USD181
2025-01-01 to 2025-03-31-402,397USD90
2024-04-01 to 2024-06-30-449,363USD91
2024-01-01 to 2024-06-30-745,836USD182
2024-01-01 to 2024-03-31-296,473USD91

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2025-01-01 to 2025-06-30-3,381,409USD181
2024-01-01 to 2024-06-30-447,155USD182

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2025-01-01 to 2025-06-3013,369USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2025-01-01 to 2025-06-3012,126,646USD181
2024-01-01 to 2024-06-30100,000USD182

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2025-01-01 to 2025-06-30-13,369USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2025-06-30-7,456,514USD
At 2024-12-31-4,391,924USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2025-04-01 to 2025-06-3010,369,127shares91
2025-01-01 to 2025-06-309,150,185shares181
2024-04-01 to 2024-06-307,903,850shares91
2024-01-01 to 2024-06-307,903,850shares182

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2025-04-01 to 2025-06-3010,369,127shares91
2025-01-01 to 2025-06-309,150,185shares181
2024-04-01 to 2024-06-307,903,850shares91
2024-01-01 to 2024-06-307,903,850shares182

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-0.26USD/shares91
2025-01-01 to 2025-06-30-0.33USD/shares181
2024-04-01 to 2024-06-30-0.06USD/shares91
2024-01-01 to 2024-06-30-0.09USD/shares182

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-0.26USD/shares91
2025-01-01 to 2025-06-30-0.33USD/shares181
2024-04-01 to 2024-06-30-0.06USD/shares91
2024-01-01 to 2024-06-30-0.09USD/shares182

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2025-06-3013,137USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2025-01-01 to 2025-06-30192,053USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-2,663,904USD91
2025-01-01 to 2025-06-30-3,028,272USD181
2024-04-01 to 2024-06-30-427,757USD91
2024-01-01 to 2024-06-30-699,483USD182

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2025-06-3010,349,549USD
At 2024-12-3113,057USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2025-06-30809,002USD
At 2024-12-311,024,334USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2025-04-01 to 2025-06-302,663,904USD91
2025-01-01 to 2025-06-303,028,272USD181
2024-04-01 to 2024-06-30427,757USD91
2024-01-01 to 2024-06-30699,483USD182

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2025-04-01 to 2025-06-30651,784USD91
2025-01-01 to 2025-06-30651,784USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2025-06-3012,575,983shares
At 2024-12-317,903,850shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2025-06-308,735,323USD
At 2024-12-313,455USD
At 2024-06-3063,326USD
At 2023-12-31410,481USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2025-06-3017,068,433USD
At 2024-12-312,954,764USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2025-06-301,614,226USD
At 2024-12-319,602USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2025-04-01 to 2025-06-302,012,120USD91
2025-01-01 to 2025-06-302,376,488USD181
2024-04-01 to 2024-06-30427,757USD91
2024-01-01 to 2024-06-30699,483USD182

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2025-01-01 to 2025-06-30232USD181

Nonoperating interest expense

Interest expense presented outside operating results. It differs from total interest expense when some borrowing cost is classified as operating or capitalized.

PeriodValueUnitDays
2025-04-01 to 2025-06-3023,054USD91
2025-01-01 to 2025-06-3061,086USD181
2024-04-01 to 2024-06-3022,123USD91
2024-01-01 to 2024-06-3049,031USD182

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2025-04-01 to 2025-06-301,711USD91
2025-01-01 to 2025-06-30-36,318USD181
2024-04-01 to 2024-06-30-21,606USD91
2024-01-01 to 2024-06-30-46,353USD182

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2025-01-01 to 2025-06-3011,953,046USD181

Inspect the source

Entity
APIMEDS PHARMACEUTICALS US, INC. / CIK 0001894525
Captured
2026-09-21T17:33:45.237Z
SEC response SHA-256
762100d6aad4bafef86c3c895afaca21f77dba6e77f7535f3302d677a991a76b

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001894525.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))